• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Oncology

Neoadjuvant Chemoimmunotherapy for Lung Cancer – A Meta-Analysis

byDaniel GoldshteinandSze Wah Samuel Chan
April 1, 2024
in Chronic Disease, Oncology
Reading Time: 3 mins read
Lung cancer collage: an older man beside an engraved pair of lungs, a snapped cigarette and a small paper house
Share on FacebookShare on TwitterShare on LinkedIn

1. The overall survival had a significant hazard ratio (0.65) when comparing neoadjuvant chemoimmunotherapy to neoadjuvant chemotherapy.

2. Both groups had similar rates of treatment (and surgical) related adverse events.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Recent studies have shown evidence for neoadjuvant immunotherapy combined with chemotherapy in resectable NSCLC, though conflicting approvals between regions underscore the need for comprehensive meta-analyses to assess efficacy across different patient subgroups and treatment regimens. This systematic review and meta-analysis considered recent randomized control trials (RCTs) as well as non-RCTs. Endpoints of interest included event-free survival (EFS), overall survival (OS), major pathological response (MPR), pathological complete response (pCR), surgical resection rates, and safety. With regards to OS across all patients, when comparing neoadjuvant chemoimmunotherapy vs neoadjuvant chemotherapy, the HR was 0.65 (significant). The HR for OS for PD-L1 levels of 1% or greater was 0.49 (significant) however in PD-L1 levels less than 1%, the HR was 0.89 (non-significant). With regards to EFS across all patients, when comparing neoadjuvant chemoimmunotherapy vs neoadjuvant chemotherapy, the HR was 0.59 (significant). Generally, this improvement was seen across age groups, sex, and histology. EFS in stage II showed an HR 0.71 (significant) and in stage III the HR was 0.54 (significant). EFS in PD-L1 levels less than 1% showed an HR 0.74 (significant), in PD-L1 levels of 1% to 49% the HR was 0.56 (significant) and in PD-L1 50% or greater the HR was 0.40 (significant). With regards to pathological response, the relative risk (RR) for MPR was 3.42 (significant), the RR for pCR was 5.52 (significant) when comparing neoadjuvant chemoimmunotherapy vs neoadjuvant chemotherapy. The RR for undergoing surgery was 1.05 (significant), and the RR for R0 resection was 1.05 (significant). Regarding safety, there were no significant differences in the relative risk for grade 3-5 treatment (or surgical) related adverse events between both groups. The strengths of this study include its methodology and the number of patients, while the limitations include treatment variability across studies. Overall, this review found that neoadjuvant chemoimmunotherapy had improved endpoints compared to neoadjuvant chemotherapy with similar safety rates.

Click to read the study in JAMA Oncology

Relevant Reading: Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: a systematic review and meta-analysis.

RELATED REPORTS

Lung cancer screening models show variable performance across populations

Guideline-based lymph node sampling is not associated with increased postoperative complications in lung cancer

In-Depth [systematic review and meta-analysis]: Databases MEDLINE and Embase were searched from Jan 2013 to Oct 2023, with single-arm trials and RCTs as part of the inclusion criteria. Combined radiotherapy or EGFR mutations were excluded. The search found 602 unique results, with 42 publications and 6 abstracts extracted, and a total of 5431 patients included. With regards to OS across all patients, when comparing neoadjuvant chemoimmunotherapy vs neoadjuvant chemotherapy, the HR was 0.65 (95%CI, 0.54-0.79; I2 = 0%). The HR for OS for PD-L1 levels of 1% or greater was 0.49 (95%CI, 0.33-0.73; I2 = 48.5%) however in PD-L1 levels less than 1%, the HR was 0.89 (95%CI, 0.66-1.19; I2 = 0%). With regards to EFS across all patients, when comparing neoadjuvant chemoimmunotherapy vs neoadjuvant chemotherapy, the HR was 0.59 (95%CI, 0.52-0.67; I2 = 14.9%). Generally, this improvement was seen across age groups, sex, and histology. EFS in stage II showed an HR 0.71 (95%CI, 0.55-0.92; I2 = 0%) and in stage III the HR was 0.54 (95% CI, 0.48-0.62; I2 = 0%). EFS in PD-L1 levels less than 1% showed an HR 0.74 (95%CI, 0.62-0.89; I2 = 0%), in PD-L1 levels of 1% to 49% the HR was 0.56 (95%CI, 0.42-0.73; I2 = 41.3%) and in PD-L1 50% or greater the HR was 0.40 (95%CI, 0.28-0.56; I2 = 32.1%). With regards to pathological response, the relative risk (RR) for MPR was 3.42 (95%CI, 2.83-4.15; I2 = 31.2%), the RR for pCR was 5.52 (95%CI, 4.25-7.15; I2 = 27.4%) when comparing neoadjuvant chemoimmunotherapy vs neoadjuvant chemotherapy. The RR for undergoing surgery was 1.05 (95%CI, 1.02-1.09; I2 = 31.8%), and the RR for R0 resection was 1.05 (95%CI, 1.02-1.08; I2 = 0%). Regarding safety, there were no significant differences in the relative risk for grade 3-5 treatment (or surgical) related adverse events between both groups. Generally, there was a low risk of bias among RCTs, and for non-RCTs bias concerns were mostly associated with inadequate length of follow-up. Overall, this review found that neoadjuvant chemoimmunotherapy had improved endpoints compared to neoadjuvant chemotherapy with similar safety rates.

Image: PD

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: chemo-immunotherapylung cancerperi-operative immunotherapy
Previous Post

Pazopanib does not improve disease-free survival post-metastasectomy for renal cell carcinoma patients

Next Post

The Scan by 2 Minute Medicine®: Early Onset Cancers in Young Lives, Swine to Save: Cross-Species Organ Transplant, Blinded by Wonder: The Risks of Viewing a Solar Eclipse Unprotected, Alternative Meat: To Eat or Not to Eat?

RelatedReports

Lung cancer screening collage: a smiling white-haired man beside engraved lungs with a magnifying glass over the upper lobe
Oncology

Lung cancer screening models show variable performance across populations

June 29, 2026
Lung cancer collage: engraved lungs with the trachea and branching bronchi above a knitted wool scarf and a pine sprig
Chronic Disease

Guideline-based lymph node sampling is not associated with increased postoperative complications in lung cancer

June 9, 2026
Diabetes collage: a lidded sugar bowl inside a blue paper circle, with a whole apple and a bunch of leafy greens
Weekly Rewinds

2 Minute Medicine Rewind June 8, 2026

June 8, 2026
Lung disease collage: engraved alveoli clusters wrapped in capillaries, coiled oxygen tubing with nasal prongs and a feather
Oncology

Positive lung cancer screens frequently receive suboptimal follow-up

December 15, 2025
Next Post
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!

The Scan by 2 Minute Medicine®: Early Onset Cancers in Young Lives, Swine to Save: Cross-Species Organ Transplant, Blinded by Wonder: The Risks of Viewing a Solar Eclipse Unprotected, Alternative Meat: To Eat or Not to Eat?

Heart disease collage: an engraved anatomical heart over a ribbon with a steady ECG trace, and three ECG electrode leads

Microplastics and nanoplastics linked to higher risk of cardiovascular events

Melanoma collage: a magnifying glass over an even mole and an uneven one on skin, with a sun hat and sunglasses

Individualized cancer mRNA-based cancer therapy shows benefit in patients with high-risk melanoma on immunotherapy

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Large genetic association study identifies additional Alzheimer disease risk loci and candidate pathways
  • Pelacarsen lowers lipoprotein(a) but does not reduce major cardiovascular events in patients with established cardiovascular disease
  • Durvalumab plus enfortumab vedotin was approved for perioperative treatment of muscle-invasive bladder cancer
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.